Loading...
Loading...
In a report published Wednesday, Oppenheimer analyst Ling Wang initiated coverage on
Rockwell MedicalRMTI with an Outperform rating and $24.00 price target.
In the report, Oppenheimer noted, “We are initiating coverage on RMTI with an Outperform rating and price target of $24. We expect RMTI shares to have significant upside to be driven by the potential regulatory approval of Triferic™ as iron replacement therapy for chronic kidney disease (CKD) patients on hemodialysis in 1Q15, possible market launch of both Triferic™ and Calcitriol in 1H15 and significant top and bottom line growth (we project RMTI reaching profitability in 2015 assuming Triferic™ approval).”
Rockwell Medical closed on Tuesday at $9.51.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in